Anavex Life Sciences Corp (AVXL)

[georgejjl]

So think about the 43 subjects taking 50 mg per day in the Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia who achieved an average improvement of 2 point over the baseline and 4 point improvement over the placebo cohort at 14 weeks into the trial.

Click on the image below:



Imagine the the additional improvement after 52 weeks on the Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001.

Good luck and GOD bless,